Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global X Autonomous & Electric Vehicles — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Global X Autonomous & Electric Vehicles trades at $35.85. The key difference: Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DRIV | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $42.53 |
52-Week Low | $205.48 | $25.23 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
DRIV trades at $35.92, up 0.98% on the day, with a bullish technical signal supported by moving averages and ADX indicators. The stock shows strong momentum, though the short-term RSI suggests overbought conditions. Recent news highlights global EV sales growth and China's aggressive expansion, benefiting the sector. A dividend of $0.07 is scheduled for July 2026, adding income potential.
Outlook remains positive due to sector tailwinds from rising EV adoption and fuel price pressures. Key risks include competitive threats from Chinese automakers and regulatory delays. Analysts are generally bullish, but investors should monitor valuation gaps and execution risks amid rapid industry shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
